1. Escin

Escin, a natural compound of triterpenoid saponins that can be isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent.

For research use only. We do not sell to patients.

Escin Chemical Structure

Escin Chemical Structure

CAS No. : 6805-41-0

Size Price Stock Quantity
100 mg USD 50 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Escin

  • Biological Activity

  • Purity & Documentation

  • Customer Review

Description

Escin, a natural compound of triterpenoid saponins that can be isolated from horse chestnut (Aesculus hippocastanum) seeds, can be used as a vasoprotective anti-inflammatory, anti-edematous and anti-nociceptive agent[1].

In Vitro

Escin (1 μM, 0-5 h) stimulates phosphorylation of the GR in CFTL-12 murine mast cells[1].
Escin (0.1-1 µg/mL, 24 h) protects cells from OGD/R and rt-PA stimulaed cell damage in bEnd.3 cells[2].
Escin (0-100 μg/mL, 12-48 h) induces cell cycle arrest and apoptosis, and inhibits tumor cell proliferation in HCT116 and HCT8 cells[5].
Escin (0-80 μg/mL, 12-24 h) induces DNA damage, and upregulates p-ATM and γH2AX in HCT116 and HCT8 cells[5].
Escin (0-50 μM, 24 h) decreases mitochondrial membrane potential and induces cytochrome C release via generation of ROS, and induces apoptosis of bladder cancer cells (T24 and J82 cells )[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[2]

Cell Line: OGD/R and rt-PA stimulated bEnd.3 cells
Concentration: 0.1, 0.5 and 1 µg/mL
Incubation Time: 24 h
Result: Upregulated the expression of ZO-1 and Occludin.
In Vivo

Escin (1-5 mg/kg, p.o.) inhibits the allergic skin response in Porcine induced by Compound 48/80 (HY-115768)[1].
Escin (0.5 and 1 mg/kg, i.v.) attenuates recombinant tissue plasminogen activator (rt-PA) induced hemorrhagic transformation (HT) in mice[2].
Escin (10 mg/kg, p.o., 4 days) shows antioxidant, anti-inflammatory, antinecrotic, and anti-apoptotic effects against Con A-induced immune-mediated hepatitis in mice[3].
Escin (5-20 mg/kg, p.o., once a day, after 6 weeks of diabetes induction, for next 4 weeks) alleviates peripheral neuropathy in Streptozotocin (HY-13753) induced diabetes in rats[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Con A-induced immune-mediated hepatitis mice[3]
Dosage: 10 mg/kg
Administration: p.o., 4 days
Result: Decreased the peak activities of ALT (p < 0.01), AST (p < 0.001), and LDH.
Ameliorated hepatic pathological abnormalities.
Limited Con A-induced elevation in Ly6G-positive cell in liver.
Clinical Trial
Molecular Weight

1131.25

Formula

C55H86O24

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

OC[C@]12[C@](CC(C)([C@H]([C@@H]2OC(C)=O)[R])C)([H])C3=CC[C@@]([C@@]4([C@@]([C@](C)([C@H](CC4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(O)=O)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)CO)O)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)CO)([H])CC8)C)([H])[C@]8(C)[C@@]3(C[C@H]1O)C.CC(OC[C@]9%10[C@](CC(C)([C@H]([C@@H]%10O)[R])C)([H])C%11=CC[C@@]([C@@]%12([C@@]([C@](C)([C@H](CC%12)O[C@H]%13[C@@H]([C@H]([C@@H]([C@H](O%13)C(O)=O)O[C@@H]%14O[C@@H]([C@H]([C@@H]([C@H]%14O)O)O)CO)O)O[C@@H]%15O[C@@H]([C@H]([C@@H]([C@H]%15O)O)O)CO)CO)([H])CC%16)C)([H])[C@]%16(C)[C@@]%11(C[C@H]9O)C)=O.[O]C(/C(C)=C\C)=O.[O]C(/C(C)=C/C)=O.[O]C(/C(C)=C\C)=O.[O]C(/C(C)=C/C)=O.[Aescin A].[Aescin B].[(E)].[(Z)].[Aescin C].[Aescin D].[(Z)].[(E)]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 1.92 mg/mL (1.70 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.8840 mL 4.4199 mL 8.8398 mL
5 mM --- --- ---
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.8840 mL 4.4199 mL 8.8398 mL 22.0994 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Escin
Cat. No.:
HY-B2114
Quantity:
MCE Japan Authorized Agent: